

2nd GLOBAL PHARMA SUMMIT

July 18-19, 2019 | Valencia, Spain

PHARMA SUMMIT 2019



SCIENTIFIC TRACKS & ABSTRACTS DAY 1

DAY 1 SESSIONS

JULY 18, 2019

Formulation R&D |
Pre-Formulation Studies | Pharmaceutical Formulations

SESSION CHAIR

Adam Frosh
Lister Hospital, United Kingdom

SESSION INTRODUCTION

- Title:** Synthesis characterization of 1-substituted biphenyl derivatives as anti-oxidant agents
Sridhar Siddiraju, Malla Reddy College of Pharmacy, India
- Title:** Stability indicating method development and validation for the determination of Alprazolam, Clidinium Bromide and Dicyclomine hydrochloride by RP-HPLC
Lal Prasanth M L, DM WIMS College of Pharmacy, India

2nd GLOBAL PHARMA SUMMIT

July 18-19, 2019 | Valencia, Spain

Sridhar Siddiraju, Asian J Biomed Pharmaceut Sci 2019, Volume 9

SYNTHESIS CHARACTERIZATION OF 1-SUBSTITUTED BIPHENYL DERIVATIVES AS ANTI-OXIDANT AGENTS

Sridhar Siddiraju

Malla Reddy College of Pharmacy, India

A series of [1, 1'-biphenyl]-4-yl)-3-substitued 2-en-1-one derivatives (4a-h) were synthesized by general acylation methods and [1, 1'-biphenyl]-4-yl)2-oxyethyl substituted derivatives were synthesized by Friedal-crafts acylation and then followed by cyclization of respective derivatives afforded targeted compounds (5a-d). The newly synthesized derivative compounds were characterized by IR, H1NMR, 13C NMR, mass analyses and screened for their *in vitro* antioxidant activity (Scavenging of hydrogen peroxide, scavenging of superoxide radical methods).

BIOGRAPHY

Sridhar Siddiraju has completed his PhD from Berhampur University, India. He is the Professor of Department of Pharmaceutical Chemistry, Malla Reddy College of Pharmacy. He has over 35 publications in various reputed journals. He is Editorial Board Member of reputed Journals.

drss.chem@gmail.com



Note:

2nd GLOBAL PHARMA SUMMIT

July 18-19, 2019 | Valencia, Spain

Lal Prasanth M L, Asian J Biomed Pharmaceut Sci 2019, Volume 9

STABILITY INDICATING METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF ALPRAZOLAM, CLIDINIUM BROMIDE AND DICYCLOMINE HYDROCHLORIDE BY RP-HPLC

Lal Prasanth M L

DM WIMS College of Pharmacy, India

A simple, accurate, precise method was developed for the simultaneous estimation of the Dicyclomine hydrochloride, Clidinium bromide and Alprazolam in Tablet dosage form. Chromatogram was run through Kromasil 250 x 4.6 mm, 5m. Mobile phase containing buffer and Acetonitrile in the ratio of 40:60 was pumped through column at a flow rate of 1ml/min. Buffer used in this method was OPA buffer at pH 2.8. Temperature was maintained at 30°C. Optimized wavelength for Dicyclomine hydrochloride, Clidinium bromide and Alprazolam was 225nm. Retention time of Dicyclomine hydrochloride, Clidinium bromide and Alprazolam were found to be 2.473min, 3.842min and 5.218min. %RSD of system precision for Dicyclomine hydrochloride, Clidinium bromide and Alprazolam were and found to be 0.3, 0.7 and 1.2 respectively. %RSD of method precision for Dicyclomine hydrochloride, Clidinium bromide and Alprazolam were and found to be 0.9, 0.5 and 0.5 respectively. Percent recovery was obtained as 99.86%, 100.33% and 100.45% for Dicyclomine hydrochloride, Clidinium bromide and Alprazolam respectively. LOD, LOQ values are obtained from regression equations of Dicyclomine hydrochloride, Clidinium bromide and Alprazolam were 0.41 ppm, 0.03ppm, 0.005ppm, 1.24ppm and 0.10ppm, 0.01ppm respectively. Regression equation of Dicyclomine hydrochloride was $y = 8451x + 13349$, Clidinium bromide was $y = 13323x + 6412$ and of Alprazolam was $y = 90717x + 3843$.

BIOGRAPHY

Lal Prasanth M L is from DM WIMS College of Pharmacy, India. His research findings mainly focus on stability indicating method development and validation for the determination of Alprazolam, Clidinium bromide and Dicyclomine hydrochloride by RP-HPLC.

lalprasanth@yahoo.com



Note:

2nd GLOBAL PHARMA SUMMIT

July 18-19, 2019 | Valencia, Spain

PHARMA SUMMIT 2019



SCIENTIFIC TRACKS & ABSTRACTS DAY 2

DAY 2 SESSIONS

JULY 19, 2019

Formulation R&D |
Pre-Formulation Studies | Pharmaceutical Formulations

SESSION CHAIR

Adam Frosh
Lister Hospital, United Kingdom

SESSION INTRODUCTION

Title: Ultra performance liquid chromatographic method development and validation for the determination of Glecaprevir and Pibrentasvir in pharmaceutical dosage forms
Poojitha Dhulipalla, Vimta Labs Ltd., India

2nd GLOBAL PHARMA SUMMIT

July 18-19, 2019 | Valencia, Spain

Poojitha Dhulipalla, Asian J Biomed Pharmaceut Sci 2019, Volume 9

ULTRA PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF GLECAPREVIR AND PIBRENTASVIR IN PHARMACEUTICAL DOSAGE FORMS

Poojitha Dhulipalla

Vimta Labs Ltd., India

The combination of Glecaprevir and Pibrentasvir is used to treat certain types of chronic hepatitis C infection. A new analytical method was developed and validated for the simultaneous determination of the Glecaprevir and Pibrentasvir in pharmaceutical dosage form by using UPLC. In this method, Chromatogram was run through HSSC18 (1.8 μ m 2.1x 100mm) column, mobile phase containing Potassium dihydrogen orthophosphate buffer (Adjusted using 30% v/v of ortho phosphoric acid pH 3.5) and Acetonitrie in the ratio of 30:70 was pumped through column at a flow rate of 0.3ml/min. Temperature was maintained at 30°C. Optimized wavelength for Glecaprevir and Pibrentasvir was 260nm. Retention times of Glecaprevir and Pibrentasvir were found to be 0.61min and 0.92min. The total run time was 2.0min. The percentage recovery was obtained as 98.4 and 99.2% for Glecaprevir and Pibrentasvir respectively. The developed method was validated as per ICH guidelines and hence it can be used for the routine analysis in various pharmaceutical industries and drug testing laboratories.

BIOGRAPHY

Poojitha Dhulipalla has completed her M Pharmacy from JSS University, Ooty, India. She is having two years of experience as auditor in the Quality Assurance Department in Pharmaceutical industry. She has over 10 publications in various reputed journals and attended various national and international conferences.

sobhapoojitha009@gmail.com



Note: